3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
30
Active not recruiting
12
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
TIC10 compound
3
trastuzumab deruxtecan
2
umbralisib
1
ublituximab
1
pembrolizumab
1
infigratinib
1
enfortumab vedotin
1
duvelisib
1
blinatumomab
1
belumosudil
1
Rituximab
1
KD025
1
Gemcitabine
1
Crizotinib
1
Cisplatin
1
Carboplatin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Has announcements
×
pembrolizumab
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA